A case of imatinib-resistant GIST treated by sunitinib
Sakamoto, Y.; Akimoto, H.; Kojo, M.; Kawano, H.; Chinen, Y.; Morita, K.; Sugiyama, M.; Saeki, H.; Minami, K.; Soejima, Y.; Sakaguchi, Y.; Toh, Y.; Okamura, T.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(5): 827-830
2011
ISSN/ISBN: 0385-0684 PMID: 21566447 Document Number: 655745
We report a case of imatinib-resistant GIST, successfully treated by sunitinib. A 62-year-old man with high-grade fever and a huge abdominal tumor was diagnosed with malignant GIST and multiple liver metastases. We performed total gastrectomy combined with distal pancreatectomy, and splenectomy for palliation. Imatinib at a dose of 300mg/day was administered postoperatively, and the liver metastases was well controlled. After nine months, abdominal dissemination increased, and we raised the dose of imatinib to 400mg/day for the progressive state. Subsequently, we had to discontinue imatinib due to its adverse effects. Because the tumors progressed greatly while imatinib was discontinued, we changed to sunitinib. After wards, tumors reduced and his general condition improved remarkably. Although tumors progressed after five months, he was able to obtain good QOL during the administration of sunitinib. Sunitinib is useful for imatinib-resistant GIST, and may be a promising treatment even for patients with poor PS.